Double blind randomized prospective trial of bethanechol in the prevention of radiation-induced salivary gland dysfunction in head and neck cancer patients.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 25890572.
- Also identified by DOI 10.1016/j.radonc.2015.03.017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study assessed the prophylactic bethanechol use to prevent salivary gland dysfunction during radiotherapy. A total of 97 head and neck cancer patients were allocated into two groups: Bethanechol or Placebo. Bethanechol group presented significantly improve of salivary parameters. Bethanechol was effective in decreasing the salivary gland damage.
Medical subject headings
- Bethanechol
- Head and Neck Neoplasms
- Salivary Glands
- Xerostomia